TrialArthritis research & therapy2020

Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies.

Mark C Genovese et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.